Ovarian cancer laboratory findings

Jump to: navigation, search

Ovarian cancer Microchapters


Patient Information


Historical Perspective



Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors


Natural History, Complications & Prognosis


History & Symptoms

Physical Examination


Laboratory Findings

Chest X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Ovarian cancer laboratory findings

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer laboratory findings

CDC on Ovarian cancer laboratory findings

Ovarian cancer laboratory findings in the news

Blogs on Ovarian cancer laboratory findings

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Huda A. Karman, M.D.


The evaluation includes laboratory work, imaging and surgical exploration for the definite diagnosis. Routine lab work includes CBC and CMP, Serum biomarkers of of epithelial ovarian cancer includes CA125, HE4, OVA1. Serum biomarkers of the germ cell and sex cord-stromal ovarian cancer include alpha-fetoprotein, human chorionic gonadotropin, lactate dehydrogenase, estradiol, Inhibin, testosterone, androstenedione, dehydroepiandrostenedione, anti-Müllerian hormone.

Laboratory Findings


  1. 1.0 1.1 Yin BW, Lloyd KO (2001). "Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16". J Biol Chem. 276 (29): 27371–5. doi:10.1074/jbc.M103554200. PMID 11369781.
  2. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR; et al. (2005). "Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas". Cancer Res. 65 (6): 2162–9. doi:10.1158/0008-5472.CAN-04-3924. PMID 15781627.
  3. 3.0 3.1 Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H; et al. (1983). "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer". N Engl J Med. 309 (15): 883–7. doi:10.1056/NEJM198310133091503. PMID 6310399.
  4. Jacobs I, Bast RC (1989). "The CA 125 tumour-associated antigen: a review of the literature". Hum Reprod. 4 (1): 1–12. doi:10.1093/oxfordjournals.humrep.a136832. PMID 2651469.
  5. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ; et al. (2004). "Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer". Cancer Res. 64 (16): 5882–90. doi:10.1158/0008-5472.CAN-04-0746. PMID 15313933.
  6. Jashnani, KusumD; Hegde, ChandrashekarV; Munot, ShrutikaP (2013). "Alfa-fetoprotein secreting ovarian sex cord-stromal tumor". Indian Journal of Pathology and Microbiology. 56 (1): 54. doi:10.4103/0377-4929.116152. ISSN 0377-4929.
  7. Mongia SK, Rawlins ML, Owen WE, Roberts WL (2006). "Performance characteristics of seven automated CA 125 assays". Am J Clin Pathol. 125 (6): 921–7. doi:10.1309/NBA3-12W0-LANR-XYH9. PMID 16690492 PMID 16690492 Check |pmid= value (help).